Gabrielle Du Sablon

Gabrielle Du Sablon practices at Northeast Florida Endocrine and Diabetes Associates PA in Jacksonville, Florida.

Gabrielle Du Sablon's NPI, 1750804662, was assigned on July 23, 2017. Gabrielle Du Sablon holds Florida license PA9110721.

Gabrielle Du Sablon's primary practice is Northeast Florida Endocrine and Diabetes Associates PA, at 915 Monroe W St, Jacksonville, FL 32204 in Duval County. The practice phone is (904) 384-2240.

Gabrielle Du Sablon's primary practice is Northeast Florida Endocrine and Diabetes Associates PA in Jacksonville, Florida. Gabrielle Du Sablon is also affiliated with Baptist Medical Center Jacksonville. The medical group on file is Northeast Florida Endocrine and Diabetes Associates. Dmand AI also links Gabrielle Du Sablon to 3 more hospitals, 2 group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Gabrielle Du Sablon practices, 6 sites in all. Vendor and product names are available with a free account.

Physician assistant is Gabrielle Du Sablon's primary specialty in the NPI Registry, under taxonomy code 363A00000X. Gabrielle Du Sablon is licensed in Florida.

Dmand AI lists diabetic emergency, insomnia, osteoporosis, tobacco use and vitamin d deficiency among the conditions Gabrielle Du Sablon treats.

CMS data shows 1,186 Medicare services from Gabrielle Du Sablon across 8 procedure codes in 2024, for 585 Medicare patients. Medicare paid $62,463 for them.

CMS counts 585 Medicare patients who saw Gabrielle Du Sablon in 2024. The largest group is 75 to 84, with 243 patients. 75% of them have diabetes, and 75% have high blood pressure. 10% are also on Medicaid. Their average risk score is 2.33, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Gabrielle Du Sablon's median patient age at 70, with 65% women.

In 2024, Gabrielle Du Sablon wrote 1,538 Medicare Part D claims for 379 patients. 33% of them were for generic drugs. CMS names the drug for 1,227 of them, across 30 drugs with 11 or more claims each, at $663,526 in total drug cost.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 95 out of 100 for Gabrielle Du Sablon for performance year 2024, reported through an alternative payment model (APM). Gabrielle Du Sablon accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 171 general payments to Gabrielle Du Sablon from 23 drug and device companies from 2024 to 2025. Food and beverage make up the largest share, 100% of the total. Abbott Laboratories paid the most, $935.